Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Benzinga · 2d ago
Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.